Until Labs is a biotech company focused on advancing organ cryopreservation technology. The firm is working to create solutions that can preserve organs for extended periods without compromising viability. Recently, the company secured significant growth capital to accelerate its research efforts. Until Labs completed a $58 million Series A financing to fund this work. Fenwick & West acted as legal counsel on the transaction. Public disclosures did not include additional information regarding revenue, user metrics, or specific product launch timelines.

Total raised

$58M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2025